progesterone for Transgendered Persons

Phase-Based Progress Estimates
Transgendered Persons
Progesterone 200 MG - Drug
What conditions do you have?

Study Summary

This trial is testing whether or not progesterone affects testosterone levels in transwomen who are already taking estradiol as part of their gender affirming treatment. Participation will last for six months, during which time participants will have to give blood and take a pill once daily. There are no known risks for taking progesterone, but it may have benefits like increasing fat mass and breast size, and decreasing masculine hair patterns.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: 24 weeks

24 weeks
Breast size
Efficacy: mood
Efficacy: sleep
Efficacy: testosterone
Hair growth
Serum follicle stimulating hormone (FSH) concentrations
Serum luteinizing hormone (LH) concentrations

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Active Control

Non-Treatment Group

20 Total Participants · 2 Treatment Groups

Primary Treatment: progesterone · Has Placebo Group · Phase 2

ActiveComparator Group · 1 Intervention: Progesterone 200 MG · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 weeks

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
183 Previous Clinical Trials
37,400 Total Patients Enrolled
Sandeep Singh Dhindsa Dhindsa, MDPrincipal InvestigatorSt. Louis University

Eligibility Criteria

Age 18+ · Male Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have achieved serum estradiol >100 pg/ml at least once, based on clinical labs in past.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
Saint Louis University100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Most responsive sites:
  1. Saint Louis University: < 48 hours
Average response time
  • < 2 Days
Typically responds via